Germany

Deal after deal, Formycon was inching toward closing the gap in its annual guidance. Still, it was not enough to meet the goal, as the German biosimilars developer’s preliminary financial report reveals.

Germany’s updated digital healthcare “manifesto” document reflects the need to dovetail with EU’s EHDS and factor in advances in AI, and provide for a new system of primary care. The medtech industry calls for faster assessments of AI-enabled technology and better access to telemonitoring tools.

The US giant could pay up to $1.12bn to the German biotech after getting access to its programmable recombinase technology.

Seven new healthcare laws will be started in Germany 2026, and seven already underway – including the revamped KHAG hospital and DRGs reform law – will be completed. So goes the ministerial promise early in the new year. Medtechs signal further references to the so-far useful government dialog.

If approved, VER-01 would be the first cannabinoid-based therapy for chronic low back pain.

Pragmatic solutions are called for to ensure that German medical device manufacturing and innovation remain competitive in global terms, federal health minister Nina Warken told a hearing of medtech industry leaders.

The pharmaceutical industry has been pushing back on a deeply unpopular rebate on products deemed to be “free combination” medicines in Germany.

Deal gives NTC exclusive rights to commercialize Formycon and Klinge’s Baiama aflibercept biosimilar in Italy, expanding Formycon’s growing network of European ophthalmology partners.

As Formycon’s fourth-quarter sales and a key pembrolizumab biosimilar deal become critical to guidance, management hinted that deeper organizational changes may be required.

Inaugural cabinet office dialog session leaves German medtech optimistic about increasing central government support in the coming months, say trade associations in Medica preview.

The German group is looking at ‘single digit billion’ opportunities, chief financial officer Helene von Roeder tells Scrip.

Capital tightening and shifting US regulations slowed contract manufacturing orders in Q3, though Richter sees normalization ahead as new European clients come online.